We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-of-Its-Kind Blood Test Detects Over 50 Cancer Types

By LabMedica International staff writers
Posted on 15 Sep 2025

Many cancers lack routine screening, so patients are often diagnosed only after tumors grow and spread, when options are limited. More...

A faster, less invasive approach that broadens early detection could shift outcomes by finding the disease earlier. Now, a new blood-based multi-cancer test that analyzes multiple biomarker classes can enhance early cancer detection.

Exact Sciences (Madison, WI; USA) has launched Cancerguard, the first on-market multi-cancer early detection (MCED) test to assess multiple biomarker classes from a simple blood draw. The test can detect signals from cancers responsible for over 80% of U.S. diagnoses and covers 50+ cancer types and subtypes, including high-mortality diseases such as pancreatic and ovarian.

Normal cells regularly release a small amount of healthy DNA and protein into the bloodstream. If cancer is present in the body, the cancer also releases unhealthy DNA or other markers into the bloodstream. Cancerguard identifies these DNA and protein markers in the blood, thus helping find cancer earlier when it is more treatable. The Cancerguard test is intended for people aged 50-84 with no cancer diagnosis in the last 3 years.

In test-development studies, Cancerguard achieved 68% sensitivity across six of the deadliest cancers and 64% overall sensitivity (excluding breast and prostate), finding over one-third of stage I–II cases, with 97.4% specificity. Modeling suggests pairing Exact Sciences’ MCED technology with standard screening could cut stage IV diagnoses by 42% and reduce overall cancer mortality by 18% over 10 years.

“The Cancerguard test offers a critical early warning that cancer may be present and helps inform an imaging-guided pathway to diagnosis, giving people the chance to act when it matters most,” said Dr. Tom Beer, chief medical officer for multi-cancer early detection at Exact Sciences. “As adoption grows, we’ll look back and ask how we ever settled for screening for only a few cancers while letting the majority go undetected. Like the smartphone redefined communication, Cancerguard has the power to redefine cancer detection and the future of early intervention.”

Related Links:
Exact Sciences


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.